SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-062063
Filing Date
2023-11-09
Accepted
2023-11-09 16:13:34
Documents
68
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-20230930.htm   iXBRL 10-Q 3003221
2 EX-31.1 trvi-ex31_1.htm EX-31.1 18096
3 EX-31.2 trvi-ex31_2.htm EX-31.2 18070
4 EX-32.1 trvi-ex32_1.htm EX-32.1 12327
5 EX-32.2 trvi-ex32_2.htm EX-32.2 12287
  Complete submission text file 0000950170-23-062063.txt   10610453

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trvi-20230930.xsd EX-101.SCH 57598
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trvi-20230930_lab.xml EX-101.LAB 507055
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trvi-20230930_pre.xml EX-101.PRE 356021
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT trvi-20230930_def.xml EX-101.DEF 184534
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT trvi-20230930_cal.xml EX-101.CAL 63729
62 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20230930_htm.xml XML 2063693
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 231392570
SIC: 2834 Pharmaceutical Preparations